Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements

William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating today.

Matt Phipps has given his Buy rating due to a combination of factors including NewAmsterdam Pharma’s promising developments in their ongoing trials and strategic advancements. The company has reported positive outcomes from the Alzheimer’s disease analysis of the BROADWAY trial, which, while not the primary focus, adds a unique differentiation for their drug obicetrapib compared to other lipid-lowering therapies.
Additionally, the anticipated results from the Phase II VINCENT study, which explores the effects of obicetrapib both alone and in combination with Repatha, are expected to provide important insights into its potential benefits. This study is seen as a strategic proof of concept, particularly in demonstrating the additive benefits of combining CETP and PCSK9 inhibition, which could further enhance the drug’s market potential. These developments contribute to the positive outlook and justify the Buy rating.

Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Upstream Bio, Inc., and Incyte. According to TipRanks, Phipps has an average return of -4.8% and a 39.93% success rate on recommended stocks.